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Immunohistoehemical determination of p53 overexpression 
An easy and readily available method to identify progression in superficial bladder cancer? 
Abstract  Overexpression of p53, as determined by im- 
munohistochemical staining with the murine monoclonal 
antibody DO7, was determined in specimens of 46 primary 
superficial transitional cell bladder tumours (14 TAG2, 
10 T1G2, 22 T1G3). A colon cancer specimen served as a 
positive control and normal mesenchymal cells in the spec- 
imens served as an internal negative control. An excep- 
tionally high proportion 36/46 (78%) of the specimens 
were found to stain positively for p53 in over 20% of the 
cell nuclei. After a median follow-up of 7 years, ten pa- 
tients developed progressive disease. Of these ten patients 
nine demonstrated p53 positivity, resulting in a sensitivity 
of 90%. However, 27 of the overall 36 patients (75%) with 
p53-positive tumours did not progress to a higher stage or 
metastatic disease. These findings suggest hat p53 over- 
expression is not of predictive prognostic value in super- 
ficial transitional cell carcinoma. With 7 of 14 specimens 
(50%) of Ta tumours overexpressing p53, the results were 
suggestive of p53 mutation being an early event in carcin- 
ogenesis. When the threshold was set at 50% of the cell 
nuclei overexpressing p53, 16/46 (35%) classified as p53 
positive. Of the 16 tumours staining positively for p53, 
7 (46%) progressed and 9 (56%) did not. None of the Ta 
and 16 (50%) of the T 1 tumours classified as positive. This 
more stringent definition of positivity still does not iden- 
tify p53 positivity as a single prognostic factor. With 50% 
ofT1 tumours classifying as positive, we still find that p53 
mutation may be an early event in carcinogenesis of blad- 
der cancer. 
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Introduction 
Bladder cancer is a multistage progressive disease with an 
onset typically later in life. The disease encompasses a 
wide spectrum of malignant potential ranging from a mere 
inconvenience to fatal disease. About 70% of superficial 
transitional cell bladder cancers recur and 10-20% 
progress to a higher stage, grade or metastatic disease. In 
comparison with superficial transitional cell carcinoma, 
the prognosis of muscle invasive tumours or metastatic dis- 
ease is poor. 
p53 is one of the most commonly found gene mutations 
in carcinogenesis and has been observed in 70% of colon 
cancers, 30-50% of breast cancers, 50% of lung cancers 
and 100% of small-cell ung cancers [12]. It has been 
shown to play an important diagnostic and prognostic role 
in a variety of tumours, but the molecular mechanisms by 
which it influences normal cell function and tumorigene- 
sis remain unclear, p53 functions as a tumour suppressor 
gene, monitoring the integrity of the genome and indticing 
cell cycle arrest at the G1-S checkpoint if damage is found 
[11]. This allows time for repair mechanisms to act. p53 
may play a role in inducing programmed cell death, if re- 
pair fails. 
The p53 protein is coded for by a 16- to 20-kb gene lo- 
cated on the short arm of chromosome 17. The product is 
a 393-amino-acid nuclear protein involved in the regula- 
tion of cell proliferation. The half-life of wild-type p53 is 
very short (6-20 min). However, many missense mutations 
may induce mutations, which lead to a prolonged half-life 
of about 6 h. Eighty per cent of mutations are missense mu- 
tations causing one amino acid to be substituted for an- 
other, usually altering protein conformation, and causing 
nuclear accumulation [9]. Not only mutations lead to a pro- 
longed half-life of the p53 protein, but viral gene products 
(e.g. S V40 large T antigen, the adenovirus E 1B protein and 
papillomavirus E6 protein) have been found to stabilize the 
wild-type p53 protein [14]. Furthermore, it seems that the 
stability of the p53 protein is influenced by other cellular 
oncogenic proteins uch as MDM2 [15]. 
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The protein encoded by the mutated p53 gene has a 
much longer half-life than wild-type p53 and allows for its 
detection by immunohistochemistry. Immunohistochemi- 
cal staining is a widely available, easy and accurate method 
for evaluating mutations of p53. 
Among the available antibodies, the monoclonal anti- 
bodies DO7 has been shown to have the highest specific- 
ity and sensitivity when combined with the target unmask- 
ing fluid (Kreatech, Amsterdam, The Netherlands) and 
then heated in a microwave oven for 5 min twice at 90 °C 
[1, 2]. 
The optimal treatment for superficial bladder cancer is 
difficult to assess, as there is no easy and reliable method 
for identifying patients at risk of developing progressive 
disease. The aim of this study was to determine whether 
p53 overexpression as assessed by immunohistochemical 
staining can predict the development of a higher grade, 
stage or metastatic disease in patients with superficial blad- 
der cancer and at what stage of carcinogenesis p53 over- 
expression occurs. 
Staining procedures included eparaffinisation i ethanol followed 
by washing in TRIS-buffered saline, pH 7.4. Immunohistochemical 
examination was performed with the target unmasking fluid (TUF) 
antigen retrieval method (Kreatech, Amsterdam, The Netherlands) 
to enhance antigen retrieval. Microwave oven heating was performed 
as described by Beckstead [2] using a citrate buffer pH 6. Slides were 
then incubated with the primary DO7 monoclonal ntibody at a di- 
lution of 1:200 at room temperature for 60 min or with the primary 
monoclonal ntibody Pabl801 at a dilution of 1:50 for 45 rain. The 
secondary antibody RAM/Ig was used for 45 rain at a 1:30 dilution. 
After incubation with the avidin-biotin peroxidase complex, sections 
were stained with hematoxylin. A colon cancer specimen known to 
be p53 positive was stained as a positive control. 
Classification of immunohistochemistry 
Depending on the percentage of nuclei demonstrating a positive 
staining reaction with the monoclonal ntibody DO7, tumours were 
classified into three groups: <20% positivity, 20-50% positivity and 
>50% positivity. Only staining of the cell nucleus was considered a 
positive reaction. The slides were evaluated independently b  two 
investigators. 
After evaluation of preliminary trials, the use of the antibody 
Pab 1801 was discontinued as we noticed a higher degree of back- 
ground staining in comparison with the antibody DO7. 
Patients and methods 
Patients 
Forty-six patients, 39 men and 7 women, with primary superficial 
transitional cell carcinoma of the bladder treated at the Department 
of Urology, University Hospital, Berne, between 1981 and 1993 were 
randomly selected. For these patients complete clinical, demograph- 
ic and histopathological data were available and all cases were re- 
viewed retrospectively. All patients were treated by transurethral re- 
section and the formalin-fixed, paraffin-embedded specimens were 
examined. Median patient age at diagnosis was 63.7 years (range 
44-88 years). Median follow-up was 7 years (range 1-15 years) af- 
ter initial diagnosis. 
Of the 46 patients with superficial transitional bladder cell car- 
cinoma, there were 14 patients with TaG2 and 32 patients with 
T1 disease (10 with G2 and 22 with G3 tumours) at initial diagnosis 
(Table 1). 
Immunohistochemistry 
Archival hematoxylin and eosin stained tissues were examined by a 
single pathologist (R.M.) in order to obtain representative s ctions 
from the superficial transitional bladder cancer specimens. Tumours 
were graded according to the WHO classification and staged accord- 
ing to the TNM system. Formalin-fixed, paraffin-embedded, archi- 
val tissue blocks from the 46 patients were sectioned and represen- 
tative sections were chosen. 
For immunohistochemical st ining we used the murine monoclo- 
nal antibodies DO7 (Dab, Hamburg, Germany) and Pabl801 (On- 
cogene Science Inc., Manhasset, NY) to mutant and wild-type p53. 
Table 1 Tumour stages and grades of 46 patients after transureth- 
ral resection for superficial transitional cell carcinoma 
G2 G3 Total 
Ta 14 0 14 
T1 10 22 32 
Total 24 22 46 
Results 
Taking a threshold of p53 nuclear overexpression i over 
20% of cells, 36/46 specimens (78%) were considered pos- 
itive and 10/46 (22%) negative. The positive control (co- 
lon cancer specimen) stained positively in all tumour cell 
nuclei with a distinct demarcation at the tumour edge in 
each staining procedure. The normal mesenchymal cells in 
all specimens remained negative and served as an internal 
negative control. Figures 1 and 2 show staining of differ- 
ent tissue specimens. 
The correlations between overexpression of p53, grade 
and stage were assessed (Table 2). A larger proportion of 
tumours with a higher grade or stage overexpressed p53. 
Fifty per cent of the Ta tumours and 91% of the T 1 tumours 
overexpressed p53. Of the G2- 71% and of the G3-classi- 
fied tumours 86% demonstrated positivity. If the cutoff was 
placed at >50% nuclear overexpression, one of the Ta tu- 
mours and 50% of the T1 tumours classified as positive 
(Table 2). After a median follow-up of 7 years, 10 of the 
46 patients (22%) progressed to a higher stage or devel- 
oped metastatic disease. Of these ten progressive bladder 
tumours, nine (90%) were positive for p53 in over 20% of 
the cells, whereas one (10%) did not stain positively. 
Overall 36 tumours classified as p53 positive of which 
9 (25%) developed into progressive disease and 27 (75%) 
did not (Table 3). Applying a higher threshold of over 50% 
nuclear expression, 16/46 tumours were classified as pos- 
itive. Seven tumours in the ten patients (70%) with pro- 
gressive disease classified as positive and three (30%) as 
negative. Of the 16 p53-positive tumours, 9 (56%) did not 
develop progressive disease (Table 3). Analysis of our re- 
sults shows a sensitivity of 90% with a specificity of 25% 
for progression of  bladder cancer when positivity is de- 
fined as 20% nuclear overexpression of p53. Setting the 
S 33 
cutoff point at 50% results in a decreased sensitivity of 
70% and an improved specificity of 75%. 
Fig. 1 Immunohistochemical determination of the antibody DO7 
for overexpression f p53 in a colon cancer specimen, serving as a 
positive control 
Fig. 2 Intense homogeneous overexpression f p53, as determined 
by immunohistochemistry with the antibody DO7, in a specimen with 
superficial transitional cell bladder carcinoma 
Table 2 Relationship between overexpression of p53, grade and 
stage of bladder tumours 
Total No. p53 < 20% p53 > 20% p53 > 50% 
Ta 14 7 (50%) 7 (50%) 0 (0°70) 
T1 32 3 (9%) 29 (91%) 16 (50%) 
Grade II 24 7 (29%) 17 (71%) 4 (17%) 
Grade III 22 3 (14%) 19 (86%) 12 (54%) 
Total 46 10 (22%) 36 (78%) 16 (35%) 
Table 3 Tumour progression i regard to percentage oftumour cell 
nuclei demonstrating positive immunohistochemical st ining 
Total Progression No progression 
(%) (%) 
<20% 10 1 (10%) 9 (90%) 
>20% 36 9 (25%) 27 (75%) 
<50% 30 3 (10%) 27 (90%) 
>50% 16 7 (44%) 9 (56%) 
Discussion 
The following conclusions can be drawn from our results: 
(1) p53 overexpression as determined by immunohisto- 
chemical determination is frequent in superficial bladder 
cancer; (2) the results in our group of patients do not sup- 
port the use of immunohistological p53 expression as a dis- 
criminating prognostic indicator in superficial cell carci- 
noma; and (3) p53 mutation may be an early event in car- 
cinogenesis of bladder cancer. 
Previous studies have shown changes in the p53 protein 
to occur in 11-64% of superficial transitional cell bladder 
tumonrs [3, 5, 7, 16, 21-23]. Interestingly, an exception- 
ally high proportion (78%) of superficial bladder tumours 
in our group stained positively for p53 (Ta 50%, T1 91%). 
In our study we used the murine monoclonal antibody DO7, 
which recognizes mutant and wild-type p53 for staining 
procedures. Antigen retrieval was enhanced by target un- 
masking fluid and according to the microwave procedure. 
In a comparative study of six common antibodies, DO7 
demonstrated the highest sensitivity and specificity for the 
p53 protein [1]. The most commonly used antibody, 
Pabl801, showed a lower sensitivity and specificity in the 
above-mentioned study. The use of the antibody DO7 could 
explain the high proportion of tumours with p53 overex- 
pression in our study in comparison to others at the cutoff 
point of 20%. 
In T1 bladder tumours, Sarkis et al. [17] observed a cor- 
relation between p53 overexpression a d disease progres- 
sion. Gardiner et al. [7] could not relate p53 overexpres- 
sion in T1 tumours to patient outcome and therefore did 
not support p53 immunohistochemical determination as a 
prognostic indicator in superficial bladder cancer [7]. 
Thomas et al. [23] demonstrated that significantly higher 
levels of p53 positivity (> 10% nuclear staining) were found 
in T1 bladder tumours with disease progression, but that 
tumour grade remained the most specific single predictor 
of progression [23]. In our group of patients we find a sen- 
sitivity of 90% combined with a specificity of 25% for tu- 
mour progression when both T1 and Ta tumours are in- 
cluded in the analysis. When analysing only the T 1 tumours 
the sensitivity remains 90% and the specificity drops to 
9%. 
A more stringent definition of positivity with a thresh- 
old at 50% results in positive staining of 50% of T1 tu- 
mours and none of the Ta tumours. This causes a slight 
decrease in sensitivity from 90% to 70% and improves 
specificity from 25% to 59%. These results suggest hat, 
whatever the threshold, overexpression of p53 as deter- 
mined by immunohistochemistry may not be used as a dis- 
criminating predictive factor for progression i  superficial 
bladder cancer. 
However, by setting the threshold for positivity at 50%, 
our results become more comparable with other published 
s 34 
results (between 11% and 64% of p53-positive tumours). 
Interestingly, in these studies cutoff points ranged from 0% 
to 20% of cells with p53 nuclear overexpression [7, 16, 
21-23]. One may speculate that in some instances overex- 
pression of the wild-type p53 accounts for immunoreac- 
tivity, especially when particularly sensitive methods are 
applied. Possibly other mechanisms may influence the ex- 
pression of the p53 protein such as viral gene products and 
cellular oncogenic proteins, which are known to stabilize 
wild-type p53 [11, 13, 15]. 
How the heterogeneity of p53 staining, found predom- 
inantly in specimens with a lower percentage of p53 over- 
expression, should be interpreted remains unanswered. It 
may be speculated that there are cells staining positively 
for p53, which are expressing p53 physiologically in re- 
sponse to damage or representing an early clone of cells 
with a p53 mutation in an otherwise negative neoplasm. 
Another methodological problem in this context is the 
evaluation of immunohistochemical staining for p53, as 
there is no standardized form of evaluation and these meth- 
ods are not quantitative. Furthermore, the intensity of stain- 
ing, a rarely discussed matter, may influence the interpre- 
tation of results. Esrig et al. [4] reported that the intensity 
of staining varies due to the location of mutations. Not only 
do staining properties vary according to the location of mis- 
sense mutations, but also different mutant alleles of the p53 
gene may have different biological and chemical proper- 
ties. It has been proposed that cancer patients with differ- 
ent p53 mutant alleles may have a different prognosis [13]. 
Esrig et al. [4] reported no evidence of p53 mutations 
by molecular analysis in 29% of bladder tumours with pos- 
itive p53 immunoreactivity using the antibody Pabl801. 
This indicates that either immunohistochemical staining is 
more sensitive than single-strand conformational polymor- 
phism analysis in detecting p53 mutations or that discor- 
dant cases represent tumours with accumulation of wild- 
type p53 protein without mutations at the p53 locus. 
Greenblatt et al. [8] reviewed 84 studies comparing im- 
munohistochemical determination with sequencing in the 
same tumour sets and found positive immunohistochemi- 
cal staining in 44% of tumours, while only 36% contained 
mutations recognized by single-strand conformational 
polymorphism analysis [8]. The sensitivity of immunohis- 
tochemical determination for p53 mutations in these stud- 
ies was in the range of 36-100% and the positive predic- 
tive value was 63% (range 8-100%). Thus, results must be 
interpreted with caution. 
p53 nuclear overexpression has been suggested to be an 
early event, because it occurs in a high percentage of pa- 
tients with carcinoma in situ [18, 20]. Whether carcinoma 
in situ does progress to invasive bladder cancer emains 
unclear. Possibly the high percentage of p53 positivity in 
carcinoma in situ is more suggestive of a different molec- 
ular pathway leading to cancerogenesis. This agrees with 
the theory that carcinoma in situ turnout cells are so undif- 
ferentiated that they cannot grow invasively, p53 overex- 
pression has been shown to correlate significantly with 
grade and stage, which suggests that p53 inactivation might 
be an early event in bladder cancer [24]. In the present 
study the association with grade and stage and the high per- 
centage of p53 overexpression in Ta tumours further im- 
plicate that p53 inactivation may occur early in the evo- 
lution of bladder cancer. Possibly further genetic altera- 
tions are necessary to induce aggressive tumour growth. 
It has been suggested that p53 staining might be predic- 
tive of chemosensitivity. Doxorubicin treatment can alter 
the p53 status of bladder tumours and p53 overexpression 
has been associated with doxorubicin resistance in the his- 
tocultures of seven superficial Ta/T1 and nine invasive 
T2-T4 tumours [6]. Further research found p53 overex- 
pression to be of independent prognostic value for survi- 
val in patients with invasive bladder cancer treated with 
neoadjuvant chemotherapy in a cohort of 90 patients [19]. 
Possibly p53 status will prove to be of prognostic value 
for therapy forms that influence the cell cycle. Further stud- 
ies are needed to elucidate the potential value of p53 im- 
munohistochemistry in predicting outcome and therapeu- 
tic response in selected patient groups. 
Conclusion 
Based on our results p53 overexpression is not a single pre- 
dictive factor in the evaluation of superficial bladder can- 
cer. In our study population, positive p53 staining was a 
frequent event, suggesting that p53 mutation may occur 
early in superficial transitional cell carcinogenesis. Al- 
though immunohistochemical determination is a simple 
and readily available procedure, the evaluation can prove 
difficult and the predictive value is limited. As p53 inac- 
tivation seems to be one step in a multistage carcinogene- 
sis, further studies including other tumour suppressor 
genes and oncogenes are required. Since it seems unlikely 
that one genetic event is responsible for tumour progres- 
sion in bladder cancer, this limited information obtained 
from p53 analysis is not surprising. 
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